# Copper

```text
DRUG INFORMATION

  ADULT
    - Insert a single Paragard at the fundus of the uterine cavity. Remove Paragard no
      later than 10 years from the date of insertion. ( 2.1 ) Insert and remove Paragard
      only if you are a healthcare provider trained on these procedures. ( 2.1 ) See the
      Full Prescribing Information for recommended timing of insertion preparation
      instructions, insertion procedures, postplacement management, and instructions on
      removing Paragard.
      Source: US FDA label for copper (ParaGard T 380A), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - No child dose in this label. That usually means untested in children, not
      unsuitable - use a paediatric source.
      Source: Read and found silent: the US FDA label for copper (ParaGard T 380A),
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for copper (ParaGard T 380A),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for copper (ParaGard T 380A),
      retrieved 2026-08-29

  PREGNANCY   [ AVOID ]
    The label says not to use it. Read the quote below before deciding.
    - Risk Summary Use of Paragard is contraindicated for use in pregnant females
      because there is no need for pregnancy prevention in a female who is already
      pregnant and Paragard may cause adverse pregnancy outcomes.
      Source: US FDA label for copper (ParaGard T 380A), section 'pregnancy', retrieved
      2026-08-29
    - If a female becomes pregnant with Paragard in place, there is an increased risk of
      miscarriage, sepsis, premature labor, and premature delivery [see
      Contraindications ( 4 ) and Warnings and Precautions ( 5.1 , 5.2 ) ] .
      Source: US FDA label for copper (ParaGard T 380A), section 'pregnancy', retrieved
      2026-08-29
    - Advise the female of the potential risks if pregnancy occurs with Paragard in
      place.
      Source: US FDA label for copper (ParaGard T 380A), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Studies on Paragard and birth defects have not been conducted. 8.2 Lactation Risk
      Summary No difference has been detected in concentration of copper in human milk
      before and after insertion of copper IUSs, including Paragard.
      Source: US FDA label for copper (ParaGard T 380A), section 'use in specific
      populations', retrieved 2026-08-29
    - There is no information on the effect of copper in a breastfed child or the effect
      on milk production.
      Source: US FDA label for copper (ParaGard T 380A), section 'use in specific
      populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for Paragard and any potential adverse effects on
      the breastfed child from Paragard. 8.4 Pediatric Use The safety and effectiveness
      of Paragard have been established in females of reproductive potential.
      Source: US FDA label for copper (ParaGard T 380A), section 'use in specific
      populations', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)